CRISPR Therapeutics AG (CRSP) is priced at $123.71 after the most recent trading session. At the very opening of the session, the stock price was $118.32 and reached a high price of $124.15, prior to closing the session it reached the value of $119.98. The stock touched a low price of $118.32.
Recently in News on May 25, 2021, CRISPR Therapeutics to Participate in Upcoming Investor Conferences. CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in June:. You can read further details here
CRISPR Therapeutics AG had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $220.20 on 01/15/21, with the lowest value was $95.11 for the same time period, recorded on 05/11/21.
CRISPR Therapeutics AG (CRSP) full year performance was 96.27%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CRISPR Therapeutics AG shares are logging -43.82% during the 52-week period from high price, and 113.22% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $58.02 and $220.20.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1139346 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the CRISPR Therapeutics AG (CRSP) recorded performance in the market was -19.20%, having the revenues showcasing -7.60% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 9.09B, as it employees total of 410 workers.
Specialists analysis on CRISPR Therapeutics AG (CRSP)
During the last month, 13 analysts gave the CRISPR Therapeutics AG a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 2 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 131.27, with a change in the price was noted -76.17. In a similar fashion, CRISPR Therapeutics AG posted a movement of -38.11% for the period of last 100 days, recording 1,795,284 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CRSP is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Trends and Technical analysis: CRISPR Therapeutics AG (CRSP)
Raw Stochastic average of CRISPR Therapeutics AG in the period of last 50 days is set at 67.33%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 98.44%. In the last 20 days, the company’s Stochastic %K was 90.53% and its Stochastic %D was recorded 85.13%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -19.20%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -15.54%, alongside a boost of 96.27% for the period of the last 12 months. The shares increased approximately by 12.64% in the 7-day charts and went down by 19.48% in the period of the last 30 days. Common stock shares were lifted by -7.60% during last recorded quarter.